Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

27
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
27
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

733
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
733
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

31
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
31
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

142
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
142
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

435
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
435
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

17
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
17

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Missing Algorithm: Cardiovascular Risk and Menopause Hormone Therapy.

European journal of preventive cardiology·2026
Same author

Walking on Collaterals: Unveiling Discrepancies in Gender-Based Variances in Peripheral Arterial Disease.

Cureus·2025
Same author

Use of suture-mediated closure device system after inadvertent medport placement in the subclavian artery leading to multi-focal ischaemic infarct: a case report.

European heart journal. Case reports·2024
Same author

Management of Persistent Left Superior Vena Cava: Overcoming Lead and Vascular Complications With Transcatheter Pacing System Implantation.

Cureus·2024
Same author

Diagnosing Alzheimer's disease: Which dementia screening test to use in elderly Puerto Ricans with mild cognitive impairment and early Alzheimer's disease?

Alzheimer's & dementia (Amsterdam, Netherlands)·2024
Same author

Effect of salinity on microplastic accumulation and osmoregulatory toxicity in the fiddler crab Minuca rapax.

Marine pollution bulletin·2023

Related Experiment Video

Updated: Sep 16, 2025

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.3K

Managing Thyrotoxicosis in Acute Heart Failure.

Maria A Rodriguez-Santiago1, Marcel A Mesa-Pabón1

  • 1Division of Cardiology, Department of Internal Medicine, University of Puerto Rico, San Juan, Puerto Rico.

JACC. Case Reports
|July 11, 2025
PubMed
Summary

Thyrotoxicosis can cause heart failure, but beta-blockers are crucial for managing symptoms like rapid heart rate. This case shows tailored beta-blocker use is key for thyrotoxic cardiac failure, especially with normal diastolic function.

Keywords:
acute heart failureatrial fibrillationbeta blockertachycardia-mediated cardiomyopathythyroid stormthyrotoxicosis

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.8K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.6K

Related Experiment Videos

Last Updated: Sep 16, 2025

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.3K
Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

24.8K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

13.6K

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Thyrotoxicosis, a condition of excess thyroid hormone, can precipitate high-output cardiac failure.
  • Beta-blockers are frequently employed to manage the hyperadrenergic state in thyrotoxicosis, despite potential contraindications in decompensated heart failure.

Observation:

  • A case of a 38-year-old female presenting with thyroid storm, atrial fibrillation, and volume overload is detailed.
  • Echocardiography demonstrated severely reduced left ventricular systolic function with preserved diastolic function.
  • Initial management involved esmolol, followed by a successful transition to propranolol.

Findings:

  • The patient's cardiac dysfunction was primarily driven by sustained tachycardia and reduced systemic vascular resistance.
  • Tailored beta-blocker therapy was effective in managing the thyrotoxic cardiac failure.

Implications:

  • Clinicians should consider thyrotoxic cardiac failure, particularly when diastolic function is normal, in patients with unexplained heart failure.
  • Individualized beta-blocker selection and titration are essential for optimizing outcomes in thyrotoxic cardiomyopathy.